CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and ...
Korro Bio, Inc. ( (KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.
Blackford Capital ("Blackford”), a leading lower middle market private equity firm, is pleased to announce the appointment of ...
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Korro Bio (KRRO – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback